Mersana Therapeutics Presents Preclinical Data from its Innovative Dolasynthen and Immunosynthen ADC Platforms at American Association for Cancer Research 2020 Virtual Annual Meeting

Stock Information for Mersana Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Mersana Therapeutics Inc.

Mersana Therapeutics to Participate in Guggenheim's 6th Annual Biotechnology Conference
Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023
Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056
Mersana Therapeutics Announces Changes in Leadership
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.